Ipsen SA (0MH6)
London Exchange · UK · prices in EUR · close of 21 Oct 2026
Key indicators
| Last close | EUR 152.30 |
|---|---|
| 52-week range | 114.78 – 174.90 |
| Return, 1 month / 3 months | +1.1% / −6.1% |
| Return, 1 year / 3 years | +29.6% / +31.6% |
| Trend | Below its 200-day average |
| RSI (14) | 58 |
| Volatility (1 year) | 30.4% |
| Worst drawdown (1 year) | -18.7% |
| Average daily value traded | 2.87M EUR |
| Dividend yield | 1.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Ipsen is a pharmaceutical company based in France that develops and markets prescription medicines. Its work centres on oncology, neuroscience and rare diseases, and it supplies treatments to hospitals and specialist physicians in many countries. Products include therapies for neuroendocrine tumours, movement disorders and spasticity, along with drugs for certain cancers and rare conditions. The company also has a consumer health business that makes and sells over-the-counter products.
On this site Ipsen SA appears as a stock on the London Exchange (UK), code 0MH6, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Ipsen SA (0MH6) trades on the London Exchange in UK. It last closed at EUR 152.30 on 21 October 2026.
Its price-based Market X-Ray is 55 out of 100 (a fair price profile), ranking 1,712 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 29.6% and over the last three months it fell 6.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 50 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -1.5% | ||
| From 52-week high | -11.1% | ||
| Momentum | 48 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -6.1% | ||
| 6-month return | -6.1% | ||
| 12-month return, skipping the last month | 28.3% | ||
| Stability (higher is calmer) | 69 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 30.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -18.7% | ||
| Liquidity | 63 · Fair | Moderate trading activity. | |
| Average daily value traded | 2.87M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 45 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.1% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Income: Dividend is small or irregular.
Returns
| 1 week | +5.2% |
|---|---|
| 1 month | +1.1% |
| 3 months | −6.1% |
| 6 months | −6.1% |
| 1 year | +29.6% |
| 3 years | +31.6% |
| 5 years | +84.1% |
Signals
| 50-day / 200-day average | 154.05 / 154.65 |
|---|---|
| Golden / death cross (60 days) | Death, 2 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 4.35 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 3 Jun 2026 | EUR 1.6000 |
| 4 Jun 2025 | EUR 1.4000 |
| 30 May 2024 | EUR 1.2000 |
| 2 Jun 2023 | EUR 1.2000 |
| 31 May 2022 | EUR 1.2000 |
| 31 May 2021 | EUR 1.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.